☆ 4.6 Letter

Cutaneous adverse reactions following SARS-CoV-2 vaccine booster dose: a real-life multicentre experience

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2022)

SARS-CoV-2 vaccine-related cutaneous manifestations: a systematic review

Gianluca Avallone et al.

Summary: This study provides an extensive overview of SARS-CoV-2 vaccine-related skin manifestations through a systematic review of 229 articles. The study identifies various skin reactions such as local injection-site reactions, rashes, urticarial rashes, angioedema, and herpes zoster. The research suggests that cutaneous adverse reactions following SARS-CoV-2 vaccine administration are infrequent and not life-threatening, but monitoring and evaluation of the skin should still be provided for vaccinated patients.

INTERNATIONAL JOURNAL OF DERMATOLOGY (2022)

添加到收藏夹

Article Medicine, General & Internal

Association of a Third Dose of BNT162b2 Vaccine With Incidence of SARS-CoV-2 Infection Among Health Care Workers in Israel

Avishay Spitzer et al.

Summary: A booster dose of BNT162b2 vaccine was associated with a significantly lower risk of SARS-CoV-2 infection among health care workers who were previously vaccinated with a 2-dose series of the same vaccine. The study was conducted in Israel and included 1928 participants with a median follow-up of 39 days.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2022)

添加到收藏夹

Article Medicine, General & Internal

Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial

Arabella S. Stuart et al.

Summary: The study investigated the mixed use of different COVID-19 vaccines within the same schedule, showing that in certain conditions, heterologous vaccination can achieve similar immunogenicity to homologous vaccination, facilitating rapid global vaccine deployment.

LANCET (2022)

添加到收藏夹

Article Immunology

BNT162b2 mRNA COVID-19 vaccine Reactogenicity: The key role of immunity

Pilar Vizcarra et al.

Summary: The study showed that pre-existing SARS-CoV-2-specific cellular immunity can affect the reactogenicity of the BNT162b2 mRNA COVID-19 vaccine, with different reactions observed in various groups after vaccination.

VACCINE (2021)

添加到收藏夹

News Item Multidisciplinary Sciences

COVID VACCINE BOOSTERS: THE MOST IMPORTANT QUESTIONS

Ewen Callaway

Summary: Some countries are considering deploying extra vaccine doses in response to concerns over waning immunity and SARS-CoV-2 variants, but it is still unclear to scientists whether most people need them.

NATURE (2021)

添加到收藏夹

Cutaneous adverse reactions following SARS-CoV-2 vaccine booster dose: a real-life multicentre experience

相关参考文献

SARS-CoV-2 vaccine-related cutaneous manifestations: a systematic review

Association of a Third Dose of BNT162b2 Vaccine With Incidence of SARS-CoV-2 Infection Among Health Care Workers in Israel

Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial

BNT162b2 mRNA COVID-19 vaccine Reactogenicity: The key role of immunity

COVID VACCINE BOOSTERS: THE MOST IMPORTANT QUESTIONS

导出引文

分享论文